NYSE · CIK 0001477845
ANVS Annovis Bio, Inc.
Insider trading from SEC Form 4. Last filing May 21, 2026. Close $1.21 on Oct 9, 2026, +16% from the 52-week low and -76% from the high.
In brief
Annovis Bio, Inc. (ANVS) has 29 SEC Form 4 filings on file from 7 insiders, the latest filed on May 21, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
9 open-market trades have been scored at ANVS. The newest: Michael B Hoffman (director) bought $143k of stock on May 20, 2026, filed May 21, 2026, scored 39 (weak). The largest of the 9 shown: Michael B Hoffman (director) bought $2.0M on Oct 28, 2025, scored 58 (moderate). 2 insiders bought within 14 days of each other around Oct 28, 2025.
1 Form 144 notice of planned sales is on file, the latest filed Apr 2, 2026.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Annovis Bio, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 39Weak | Michael B Hoffman director buy | $143k 76,344 shares | +2% | +28% from low-60% from high | |
| 54Moderate | Michael B Hoffman director buy | $1.5M 713,800 shares | +28% | +87% from low-55% from high | |
| 32Weak | Michael B Hoffman director buy | $194k 45,000 shares | +2% | - | |
| 31Weak | Michael B Hoffman director buy | $160k 39,200 shares | +2% | - | |
| 31Weak | Michael B Hoffman director buy | $160k 39,200 shares | +2% | - | |
| 23Weak | Michael B Hoffman director buy | $70k 20,000 shares | +1% | - | |
| 20Weak | Michael B Hoffman director buy | $32k 15,000 shares | +1% | - | |
| 58Moderate | Michael B Hoffman director buy | $2.0M 975,610 shares | +66% | - | |
| 48Moderate | Maria-Luisa Maccecchini President & CEO buy | $200k 97,561 shares | +9% | - |
Planned sales
Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales
| Filed | Seller | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Apr 2, 2026 | White Mark K. Director | 7,142 0.03% of outstanding | $15k | Apr 2, 2026 | none |
Transactions
Every row filed, 46 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 20, 2026 | Michael B Hoffman director | POpen-market purchase Common Stock | +2,562 | $1.75 | $4,484 | 3,291,101 | May 21, 2026 |
| May 20, 2026 | Michael B Hoffman director | POpen-market purchase Common Stock | +18,849 | $1.80 | $34k | 3,309,950 | May 21, 2026 |
| May 20, 2026 | Michael B Hoffman director | POpen-market purchase Common Stock | +54,933 | $1.90 | $104k | 3,364,883 | May 21, 2026 |
| Apr 2, 2026 | Michael B Hoffman director | POpen-market purchase Common Stock | +713,800 | $2.10 | $1.5M | 3,288,539 | Apr 3, 2026 |
| Dec 8, 2025 | Michael B Hoffman director | POpen-market purchase Common Stock | +30,000 | $4.34 | $130k | 2,559,739 | Dec 8, 2025 |
| Dec 8, 2025 | Michael B Hoffman director | POpen-market purchase Common Stock | +15,000 | $4.24 | $64k | 2,574,739 | Dec 8, 2025 |
| Nov 24, 2025 | Michael B Hoffman director | POpen-market purchase Common Stock | +1,489 | $4.13 | $6,150 | 2,482,028 | Nov 25, 2025 |
| Nov 24, 2025 | Michael B Hoffman director | POpen-market purchase Common Stock | +1,489 | $4.13 | $6,150 | 2,492,028 | Nov 25, 2025 |
| Nov 24, 2025 | Michael B Hoffman director | POpen-market purchase Common Stock | +9,200 | $3.85 | $35k | 2,491,228 | Nov 25, 2025 |
| Nov 24, 2025 | Michael B Hoffman director | POpen-market purchase Common Stock | +9,200 | $3.85 | $35k | 2,501,228 | Nov 25, 2025 |
| Nov 24, 2025 | Michael B Hoffman director | POpen-market purchase Common Stock | +415 | $4.14 | $1,718 | 2,491,643 | Nov 25, 2025 |
| Nov 24, 2025 | Michael B Hoffman director | POpen-market purchase Common Stock | +415 | $4.14 | $1,718 | 2,501,643 | Nov 25, 2025 |
| Nov 24, 2025 | Michael B Hoffman director | POpen-market purchase Common Stock | +28,096 | $4.15 | $117k | 2,529,739 | Nov 25, 2025 |
| Nov 24, 2025 | Michael B Hoffman director | POpen-market purchase Common Stock | +28,096 | $4.15 | $117k | 2,519,739 | Nov 25, 2025 |
| Nov 21, 2025 | Michael B Hoffman director | POpen-market purchase Common Stock | +10,000 | $3.49 | $35k | 2,480,539 | Nov 21, 2025 |
| Nov 21, 2025 | Michael B Hoffman director | POpen-market purchase Common Stock | +10,000 | $3.50 | $35k | 2,490,539 | Nov 21, 2025 |
| Nov 14, 2025 | Michael B Hoffman director | POpen-market purchase Common Stock | +15,000 | $2.11 | $32k | 2,470,539 | Nov 18, 2025 |
| Oct 28, 2025 | Michael B Hoffman director | POpen-market purchase Common Stock | +975,610 | $2.05 | $2.0M | 2,455,539 | Nov 12, 2025 |
| Oct 28, 2025 | Maria-Luisa Maccecchini President & CEO | POpen-market purchase Common Stock | +97,561 | $2.05 | $200k | 1,212,020 | Nov 12, 2025 |
| Sep 10, 2025 | Claudine Bruck director | MOption exercise Common Stock | +7,142 | $0.14 | $1,000 | 13,709 | Nov 12, 2025 |
| Sep 10, 2025 | Claudine Bruck director | MOption exercise Optionderivative | -7,142 | $0.00 | $0 | 0 | Nov 12, 2025 |
| Aug 29, 2025 | Michael B Hoffman director | AGrant or award Common Stock | +5,000 | $2.28 | $11k | 1,469,929 | Sep 3, 2025 |
| Aug 29, 2025 | Michael B Hoffman director | AGrant or award Common Stock | +5,000 | $2.29 | $11k | 1,474,929 | Sep 3, 2025 |
| Aug 29, 2025 | Michael B Hoffman director | AGrant or award Common Stock | +5,000 | $2.30 | $12k | 1,479,929 | Sep 3, 2025 |
| Aug 19, 2025 | Michael B Hoffman director | AGrant or award Common Stock | +6,717 | $2.60 | $17k | 1,453,001 | Aug 20, 2025 |
| Aug 19, 2025 | Michael B Hoffman director | AGrant or award Common Stock | +5,283 | $2.59 | $14k | 1,458,284 | Aug 20, 2025 |
| Aug 19, 2025 | Michael B Hoffman director | AGrant or award Common Stock | +5,545 | $2.58 | $14k | 1,463,829 | Aug 20, 2025 |
| Aug 19, 2025 | Michael B Hoffman director | AGrant or award Common Stock | +1,100 | $2.57 | $2,827 | 1,464,929 | Aug 20, 2025 |
| Jun 16, 2025 | Andrew Walsh Vice President, Finance | AGrant or award Common Stock | +500 | $2.90 | $1,450 | 500 | Jun 18, 2025 |
| Jun 13, 2025 | Michael B Hoffman director | AGrant or award Common Stock | +25,000 | $2.80 | $70k | 1,446,283 | Jun 16, 2025 |
| Jun 13, 2025 | Michael B Hoffman director | AGrant or award Common Stock | +1 | $2.83 | $3 | 1,446,284 | Jun 16, 2025 |
| Jun 10, 2025 | Reid McCarthy director | AGrant or award Common Stock | +2,000 | $2.95 | $5,900 | 9,305 | Jun 11, 2025 |
| Jun 4, 2025 | Maria-Luisa Maccecchini President & CEO | AGrant or award Common Stock | +46,000 | $3.37 | $155k | 1,114,459 | Jun 5, 2025 |
| May 29, 2025 | Michael B Hoffman director | AGrant or award Common Stock | +5,000 | $2.43 | $12k | 1,421,283 | Jun 2, 2025 |
| Nov 20, 2023 | Mark K. White director | AGrant or award Common Stock | +1,990 | $6.10 | $12k | 61,167 | Nov 22, 2023 |
| Nov 20, 2023 | Reid McCarthy director | JOther Common Stock | +0 | $0.00 | $0 | 7,305 | Nov 22, 2023 |
| Nov 20, 2023 | Michael B Hoffman director, owner | AGrant or award Common Stockindirect: The 2018 Jane and Michael Hoffman Descendants Trust | +163,880 | $6.10 | $1000k | 223,357 | Nov 22, 2023 |
| Nov 20, 2023 | Maria-Luisa Maccecchini President and CEO | AGrant or award Common Stock | +40,970 | $6.10 | $250k | 1,098,459 | Nov 22, 2023 |
| Nov 20, 2023 | Henry Hagopian III Chief Financial Officer | AGrant or award Common Stock | +820 | $6.10 | $5,002 | 1,820 | Nov 22, 2023 |
| Nov 20, 2023 | Claudine Bruck director | JOther Common Stock | +0 | $0.00 | $0 | 6,567 | Nov 22, 2023 |
| Nov 20, 2023 | Reid McCarthy director | AGrant or award Common Stock | +824 | $6.07 | $5,002 | 8,129 | Nov 21, 2023 |
| Nov 20, 2023 | Michael B Hoffman director, owner | AGrant or award Common Stockindirect: The 2018 Jane and Michael Hoffman Descendants Trust | +164,745 | $6.07 | $1.0M | 224,222 | Nov 21, 2023 |
| Nov 20, 2023 | Mark K. White director | AGrant or award Common Stock | +2,000 | $6.07 | $12k | 61,177 | Nov 21, 2023 |
| Nov 20, 2023 | Maria-Luisa Maccecchini President and CEO | AGrant or award Common Stock | +41,186 | $6.07 | $250k | 1,098,675 | Nov 21, 2023 |
| Nov 20, 2023 | Henry Hagopian III Chief Financial Officer | AGrant or award Common Stock | +824 | $6.07 | $5,002 | 1,824 | Nov 21, 2023 |
| Nov 20, 2023 | Claudine Bruck director | AGrant or award Common Stock | +1,000 | $6.07 | $6,070 | 7,567 | Nov 21, 2023 |
Insiders
Everyone who has filed a Form 4 here.
- Claudine Bruckdirector
- Henry Hagopian IIIChief Financial Officer
- Michael B Hoffmandirector, ceo, chair, officer, owner
- Maria-Luisa MaccecchiniPresident and CEO
- Reid McCarthydirector
- Andrew WalshVice President, Finance
- Mark K. Whitedirector
Questions about ANVS
Answered from the filings on this page, as of the latest one.
Are insiders buying ANVS?
No. In the last 90 days no insider at Annovis Bio, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade ANVS on the open market?
Michael B Hoffman (director) bought $143k of ANVS on May 20, 2026 and filed the Form 4 on May 21, 2026. InsiderTell scored 39 (weak).
How many insiders file Form 4 at Annovis Bio, Inc.?
7 people have filed a Form 4 at Annovis Bio, Inc., among them Claudine Bruck (director), Henry Hagopian III (Chief Financial Officer), Michael B Hoffman (director, CEO, chair and 10% owner). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.